Bringing Groundbreaking Treatments to Patients with Psychiatric and Neurodegenerative Diseases

Unleashing unique properties and biological effects of Noble gases for treatment of PTSD, Autism, Dementia

Combining revolutionary portable inhalation device with a safe therapeutic

Accelerated pathway of clinical development

Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

News Feed

Twitter Feed

Nobilis Therapeutics @NobilisTx
Four reasons why Spravato approval is WONDERFUL NEWS for Nobilis: 1) NMDA antagonism MOA validation, 2) novel adm… https://t.co/BsDHUJ0WiU
h J R
Nobilis Therapeutics @NobilisTx
An important milestone. An NMDA receptor antagonist is approved. NBTX-001 doesn’t have the psychomimetic side effec… https://t.co/rjbRPgnMF8
h J R
Nobilis Therapeutics @NobilisTx
This is what we are actively working on. This is, indeed, a crisis situation. https://t.co/CjWXQoHTef
h J R
Nobilis Therapeutics @NobilisTx
Suicide, alcohol, drug deaths reach all-time high https://t.co/3JQcvULv5w
h J R